The First People's Hospital of Yueyang
Welcome,         Profile    Billing    Logout  
 7 Trials 
40 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Xiao, Jun
NCT05058040: A Clinical Study to Evaluate the Long-Term Safety Sodium Oligomannate Capsules (GV-971)

Active, not recruiting
4
2500
RoW
Sodium Oligomannate Capsules
Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
Alzheimer Disease
01/25
04/25
NCT05181475: Long-term Efficacy and Safety Study of GV-971

Active, not recruiting
4
800
RoW
Sodium Oligomannate Capsules (GV-971)
Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
Alzheimer Disease
01/25
06/25
NCT06707194: Effect and Safety of Benzathine Penicillin Combined With Etanercept on Spondyloarthritis

Not yet recruiting
4
208
RoW
Etanercept, Benzathine Penicillin, Placebo
Nanfang Hospital, Southern Medical University
Spondyloarthritis (SpA), Ankylosing Spondylitis (AS)
09/25
09/26
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
NCT06180889: Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty

Recruiting
2
240
RoW
Enoxaparin, KN060 Low, KN060 Middle, KN060 Hight
Suzhou Alphamab Co., Ltd.
Knee Arthroplasty, Total
12/25
04/26
NCT05738694: Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma

Recruiting
2
246
RoW
Axitinib plus Toripalimab, nephrectomy
ZHOU FANGJIAN, Pfizer
Renal Cell Carcinoma, Neoadjuvant
07/25
03/26
NCT06507462: A Diagnostic Prediction Model for Prostate Cancer in Patients With PI-RADS Score 3

Recruiting
N/A
500
RoW
prostate biopsy
Anhui Provincial Hospital
Prostate Cancer
10/24
12/24
NCT06467773: TSPO-PET/MRI in Surveillance of Neuroinflammation in the Central Nervous System

Not yet recruiting
N/A
100
RoW
Radiation: PET-MRI with [18F]-DPA-714
Tongji Hospital, Wuhan Jianmin DAPENG Pharmaceutical Co., Ltd.
Central Nervous System Diseases
06/29
12/29
FAVOR IV-QVAS, NCT03977129: Quantitative Flow Ratio (QFR) Guided Revascularization Strategy for Patients Undergoing Primary Valve Surgery With Comorbid Coronary Artery Disease

Active, not recruiting
N/A
792
RoW
QFR-guided strategy, CAG-guided strategy
Ruijin Hospital, Med-X Research Institute, Shanghai Jiao Tong University
Primary Valvular Heart Disease With Comorbid Coronary Artery Disease, Planned to Undergo Elective On-pump Valve Surgery Due to Primary Mitral and/or Aortic Valvular Heart Disease
09/24
12/26
NCT06474507: Efficacy and Safety of Calculus Bovis Sativus (CBS) for Ischemic Cerebral Vascular Disease (CBSinICVD)

Recruiting
N/A
230
RoW
Calculus bovis sativus (CBS)
Tongji Hospital, Wuhan Jianmin DAPENG Pharmaceutical Co., Ltd.
Ischemic Cerebrovascular Disease, Acute Ischemic Stroke, Cerebral Small Vessel Diseases
07/29
12/29
NCT06474520: Efficacy and Safety of Calculus Bovis Sativus (CBS) for Idiopathic Inflammatory Demyelinating Disease (CBSinIIDD)

Recruiting
N/A
250
RoW
Calculus bovis sativus (CBS)
Tongji Hospital, Wuhan Jianmin DAPENG Pharmaceutical Co., Ltd.
Idiopathic Inflammatory Demyelinating Disease, Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Acute Disseminated Encephalomyelitis
07/29
12/29
5TbpMRI, NCT06612047: Comparison of 5.0T and 3.0T Biparametric Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer

Not yet recruiting
N/A
150
NA
Prostate biopsy
Anhui Provincial Hospital
Prostate Cancer
09/26
12/26
NCT06737588: The Addictive Diagnostic Value of Apparent Diffusion Coefficients to bpMRI in the Diagnosis of Prostate Cancer

Recruiting
N/A
600
RoW
Anhui Provincial Hospital
Prostate Cancer
12/26
03/27
NCT04847752: Study of Predictive Factors Related to Prognosis of Patients With Ischemic Stroke Due to Large-artery Atherosclerosis

Recruiting
N/A
1000
RoW
carotid artery stenting, CAS, carotid endarterectomy, CEA, Aspirin, ASP, Clopidogrel, plavix, Anticoagulant, warfarin, rivaroxaban, dabigatran, any other anticoagulant therapy, Statin, atorvastatin, rosuvastatin, any other statin drugs, PCSK9 inhibitor, Evolocumab, Alirocumab, any other PCSK9 inhibitors
Tongji Hospital
Ischemic Stroke, Large-Artery Atherosclerosis (Embolus/Thrombosis)
12/26
12/28
Li, luoqing
BIATICH, NCT05593380: The Effect of BIA Monitoring of Brain Edema on the Neurological Prognosis of Supratentorial Massive ICH

Recruiting
N/A
190
RoW
Parenchymal Intracranial pressure monitor, Integra Life Sciences Camino Intracranial Monitor, Treatment based on clinical and imaging observations
Xiangya Hospital of Central South University
Cerebral Hemorrhage, Hypertensive, Intracranial Hypertension, Monitoring, Critical Care, Treatment Outcome, Invasive Intracranial Pressure Monitoring, Large-volume Cerebral Hemorrhage
12/24
03/25
Petru, Edgar
innovaTV 301, NCT04697628 / 2019-001655-39: Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

Active, not recruiting
3
502
Europe, Canada, Japan, US, RoW
tisotumab vedotin, TIVDAK, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed
Seagen Inc., Genmab
Cervical Cancer
07/23
08/25
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen Inc., Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
MATAO, NCT04111978 / 2019-002264-27: MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer

Recruiting
3
540
Europe
Letrozole 2.5mg, Femara, Placebo
Swiss GO Trial Group, AGO Study Group, Arbeitsgemeinschaft Gynaekologische Onkologie Austria, Reliable Cancer Therapies, Krebsliga Schweiz, Stiftung Guido Feger, Hoffmann-La Roche, Helsana AG, Novartis Pharmaceuticals, Anticancer Fund, Belgium
Ovarian Neoplasm Epithelial, Fallopian Tube Neoplasms, Peritoneal Neoplasms, High-grade Serous Ovarian Carcinoma (HGSOC), Low-grade Serous Ovarian Carcinoma (LGSOC), Ovarian Endometrioid Carcinoma
10/25
10/30
SASCIA, NCT04595565 / 2019-004100-35: Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

Active, not recruiting
3
1332
Europe
Capecitabine, Xeloda, Carboplatin, Paraplatin, Cisplatin, Platinol, Sacituzumab govitecan, Trodelvy
German Breast Group, Gilead Sciences, Austrian Breast & Colorectal Cancer Study Group, Spanish Breast Cancer Research Group (GEICAM), ETOP IBCSG Partners Foundation, Cancer Trials Ireland, UNICANCER
HER2-negative Breast Cancer, Triple Negative Breast Cancer
03/27
03/29
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
ENGOT en-21, NCT05797831: Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

Recruiting
2/3
268
Europe, Canada, US, RoW
Navtemadlin, KRT-232, Navtemadlin Placebo
Kartos Therapeutics, Inc., European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
Endometrial Cancer
08/25
07/27
NCT04369352: Register to Describe the Treatment Pattern of Platinum-sensitive Relapsed Epithelial Ovarian Cancer Patients in Austria

Recruiting
N/A
150
Europe
Medical University Innsbruck
Recurrent Ovarian Carcinoma
12/24
08/25
Wang, Xiaoyue
QWINT-2, NCT05362058: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time

Completed
3
928
Europe, Canada, Japan, US, RoW
Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec
Eli Lilly and Company
Diabetes, Type 2 Diabetes
04/24
04/24
SURPASS-CN-INS, NCT05691712: A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes

Completed
3
257
RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Diabetes Type 2, Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases
07/24
07/24
NEPTUNE-17, NCT05838755: A Study to Evaluate Efficacy and Safety of GSK3858279 in Diabetic Peripheral Neuropathic Pain

Active, not recruiting
2
145
Europe, Canada, Japan, US, RoW
GSK3858279, Placebo
GlaxoSmithKline
Pain
10/24
01/25
Mok, Kelly
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
NCT03763604: Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

Approved for marketing
N/A
Europe, Canada, RoW
Abemaciclib, LY2835219
Eli Lilly and Company
Metastatic Breast Cancer
 
 
Huang, Xiang
NCT05908695: An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's Disease

Recruiting
4
1312
RoW
GV-971, Placebo
Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
Alzheimer's Disease
06/29
12/29
NCT05823623: Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast Cancer

Recruiting
2
30
RoW
Inetetamab, Pyrotinib, Oral Vinorelbine Tartrate
The First Affiliated Hospital with Nanjing Medical University
Breast Cancer
12/23
12/25
BIATICH, NCT05593380: The Effect of BIA Monitoring of Brain Edema on the Neurological Prognosis of Supratentorial Massive ICH

Recruiting
N/A
190
RoW
Parenchymal Intracranial pressure monitor, Integra Life Sciences Camino Intracranial Monitor, Treatment based on clinical and imaging observations
Xiangya Hospital of Central South University
Cerebral Hemorrhage, Hypertensive, Intracranial Hypertension, Monitoring, Critical Care, Treatment Outcome, Invasive Intracranial Pressure Monitoring, Large-volume Cerebral Hemorrhage
12/24
03/25
Lau, Peter
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
BGB-A317-15025-101, NCT04649385: BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors

Active, not recruiting
1
157
US, RoW
BGB-15025, Tislelizumab, BGB-A317
BeiGene
Advanced Solid Tumor
03/25
03/25
NCT05872295: IKS014 in Advanced Solid Tumors That Express HER2

Recruiting
1
165
RoW
IKS014
Iksuda Therapeutics Ltd.
Breast Cancer, Gastric Cancer, Gastroesophageal-junction Cancer
09/25
09/27
Ferraro, Danielle
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
McCartney, Amelia
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
BELLA, NCT04739670: Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer

Recruiting
2
31
RoW
Atezolizumab, Bevacizumab, Gemcitabine, Carboplatin
Peter MacCallum Cancer Centre, Australia
Metastatic Triple Negative Breast Cancer
09/25
09/25
Sahu, Arvind
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
Pan, Gang
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29

Download Options